Location
Israel, Middle East
Check Size
$500K - $3M
Investment Stage
Seed
Series A
Series B
Focus Areas
BioTech
About Investor
Ken Belotsky is Founding Partner at Negev Capital in Tel Aviv, Israel, leading seed- and Series A investments ($500 K–$3 M, sweet spot $1 M) in biotech and psychedelic drug development. His most recent deal was a $1 M Series B in Gilgamesh Pharmaceuticals. With a background as an investor-operator in life sciences, Ken drives innovation in mental health therapeutics.
Similar Investors
NP
Noah Pickholtz
Israel, Middle East
$25K - $1M
Idea
,Pre Seed
,RR
Ran Regev
Israel, Middle East
$100K - $12M
Series A
,Series B
,RG
Roy Glasberg
Israel, Middle East
$500K - $2M
Seed
,Series A
,YA
Yuval Ariav
Israel, Middle East
$500K - $3.5M
Seed
,Series A
,AF
Ariel Finkelstein
Israel, Middle East
$50K - $700K
Pre Seed
,Seed
,AS
Amy Swartz
United Arab Emirates, Middle East
$100K - $5M
Seed
,Series A
,Is this You?
Is this you? Have any edits?
Fill out our update request form and we'll update ASAP
Grow with the Right Investors
This profile is just one example. Our AI matches you with the investors who best fit your stage, industry, and vision.
Start Matching For Free